Co-Diagnostics (CODX) Tops Q2 EPS by $1.54, Beats on Revenue

Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of ($1.46), $1.54 better than the analyst estimate of ($3.00). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $132.58 thousand.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Thor Industries (THO) Misses Q4 EPS by 13c
• Tradeweb upgrades corporate bond pricing engine with machine learning